On November 4, 2026 Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, reported the presentation of initial first-in-human clinical data from the ongoing Phase 1 study of IM-1021, an investigational ROR1-targeted antibody-drug conjugate (ADC) for the treatment of advanced B-cell lymphomas, at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster will include initial results demonstrating responses across all dose levels evaluated in heavily pretreated patients with B-cell non-Hodgkin lymphoma (B-NHL). Among 19 response-evaluable patients with B-NHL, the objective response rate (ORR) was 53% (10/19), including five complete responses (CRs) and five partial responses (PRs). Among 11 response-evaluable patients with diffuse large B-cell lymphoma (DLBCL), the ORR was 64% (7/11), including three CRs and four PRs.
"At this interim read, we were encouraged to see clinical activity with IM-1021 in these heavily pretreated patients, including patients whose disease had progressed following T-cell redirecting therapies," said Bob Lechleider, M.D., Chief Medical Officer of Immunome. "These early results support our dose optimization efforts as we work to advance IM-1021 and further evaluate its potential for patients with B-cell lymphomas. The study is ongoing, and we look forward to presenting an updated dataset at ASH (Free ASH Whitepaper)."
As of the June 26, 2026, abstract data cutoff, 35 patients had received IM-1021, including 25 patients with B-NHL. Treatment-emergent adverse events (TEAEs) were reported in 92% of B-NHL patients. Grade ≥3 TEAEs occurred in 52% of B-NHL patients, of which the most common was neutropenia (44%). The patients with B-NHL had received a median of four prior lines of therapy, and prior T-cell redirecting therapy was common. Responses were observed across all dose levels tested. Dose optimization across multiple dosing regimens remains ongoing.
Presentation Details
Title: Initial results from first-in-human study of IM-1021, a ROR1-targeted antibody-drug conjugate with TOP1-inhibitor payload, in adults with advanced B-cell lymphomas
Presenter: Dr. Krish Patel (Sarah Cannon Research Institute)
Session: 629: Aggressive Lymphomas, Non-Cellular Immunotherapy including Bispecific Antibodies: Poster III
Publication Number: 5457
Location: MCCNO – Hall F
Date/Time: December 14, 2026, 6:00p.m. – 8:00p.m.
About the IM-1021-101 Trial
The Phase 1 IM-1021-101 study (ClinicalTrials.gov Identifier: NCT06823167) is an ongoing, first-in-human, open-label, multinational, multicenter dose-escalation and expansion study evaluating IM-1021 in patients with advanced B-cell lymphomas and advanced solid tumors. The study is designed to evaluate the safety and tolerability of IM-1021 and select recommended dose(s) for further study, as well as characterize preliminary antitumor activity and pharmacokinetics.
About IM-1021
IM-1021 is an investigational ROR1-targeted ADC currently being evaluated in a Phase 1 study in patients with advanced B-cell lymphomas. ROR1 is expressed in liquid and solid tumors but is largely absent in most mature tissues. IM-1021 incorporates an antibody designed to promote internalization and Immunome’s proprietary TOP1 inhibitor payload, HC74. Immunome designed IM-1021 to optimize ADC-mediated killing of ROR1-positive tumor cells. The company initiated enrollment in the Phase 1 study in the first quarter of 2025.
(Press release, Immunome, NOV 4, 2026, View Source [SID1234674228])